Answers are grounded in this paper and cite their sources.
Summary. The increasing availability of factor IX concentrates have extended their use in conditions other than factor IX deficiency and especially in combined acquired deficiencies of vitamin K dependent clotting factors. The occurrence of complications such as post‐transfusion hepatitis type B and thromboembolic episodes have prompted the International Committee on Thrombosis and Hemostasis to constitute a Task Force on the clinical use of factor IX concentrates. The various concentrates available and the basis for their method of preparation are listed. Their use in various pathological conditions other than factor IX deficiency and also the occurrence of complications in such conditions are reviewed. The conclusions and the recommendations on the indications and contraindications formulated by the Task Force on the clinical use of factor IX concentrates as issued following the 1974 Basel Meeting are summarized.
No takes yet. Share an insight, caveat, or question.
Ménaché et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: